



8 February 2021

Creso brings cannaQIX® sales inhouse to unlock further sales growth in Switzerland

Highlights:

- **Creso has taken over the marketing & sales of cannaQIX® which were outsourced to Doetsch Grether in the Swiss market over the last 3 years**
- **Creso's cannaQIX is listed with key wholesalers reaching over 2,100 pharmacies and drugstores as point of sales to the consumer**
- **The re-integration of marketing & sales of cannaQIX® will provide an improved profit margin and set the stage for further new product launches**

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to inform that it has brought the marketing and sales function of cannaQIX® inhouse, taking over from its commercial partner Doetsch Grether in Switzerland, following a growing trend of direct inbound sales enquiries and interest in cannaQIX® product .

cannaQIX® is listed with key wholesalers reaching over 2,100 point of sales to consumers which are pharmacies, pharmacy networks, drugstores, health nutrition shops and bigger retail shops such as Manor. Creso is now directly supplying all major wholesalers in the country such as Galexis, Amedis and Voigt.

Creso and Doetsch Grether worked in commercial partnership over three years. Peak sales at wholesale price level reached over CHF 230,000 in 2019. With Creso now bringing this function inhouse, it is able to improve its profit margins for cannaQIX® substantially and can set the stage for further product extensions and new product launches such as cannaDOL® in Switzerland.



cannaQIX®



cannaDOL®0.5%, 1% 100 ml gel tubes



Management Commentary

Creso's Commercial Director Dr. Gian Trepp, commented: "We are implementing phase 3 of Creso's operational launch plan by bringing the marketing & sales function of our products inhouse. While we are thankful of having benefitted from our partnership with Doetsch Grether, our direct sales model will give Creso the opportunity to expand its profit margins as it enters a new phase of growth."

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.